Tumours of the Ewing family, which comprise Ewing's sarcoma and peripheral primitive neuroectodermal tumours, are highly aggressive and mostly affect children and adolescents. They are characterized by chromosomal translocations leading to the generation of fusion proteins between EWS (or very rarely FUS) and members of the E-twenty-six (ETS) family of transcription factors that are capable of transforming cells. EWS/FLI1, the most frequent fusion, is thought to cause transformation through activation or repression of specific target genes. We present evidence demonstrating that the Wnt inhibitor and b-catenin/T-cell factor (TCF)-responsive gene DICKKOPF-1 (DKK-1) is a transcriptional target of EWS/FLI1, which can inhibit both basal and b-catenininduced transactivation of the DKK-1 promoter. Moreover, our data indicate that EWS/FLI1 has a more general effect on b-catenin/TCF-mediated transcription since it can block transactivation of a consensus b-catenin/TCF reporter construct. Consistently, Ewing tumour cells expressing different EWS/ETS translocations cannot engage b-catenin/TCF-dependent transcription, whereas silencing of EWS/FLI1 restores b-catenin responsiveness in A673 and RD-ES Ewing tumour cells. Accordingly, gene set enrichment analysis shows that b-catenin/ TCF target genes are significantly enriched among genes downregulated by EWS/FLI1 in the Ewing cell line A673. Mechanistically, the inhibitory effect of EWS/FLI1 can be overcome by a constitutively active TCF4 protein (TCF4-VP16). Moreover, EWS/FLI1 binds lymphoid enhancer factor 1, a TCF family member, and interferes with its binding to b-catenin, which could explain its negative effect on b-catenin/TCF-mediated transcription. Our results show that EWS/FLI1 inhibits both DKK-1 expression as well as b-catenin/TCF-dependent transcription, which could contribute to progression of tumours of the Ewing family.
Introduction
Ewing's family of tumours (EFT) defines a group of highly malignant tumours arising mainly in bone that most often affect children and young adults in the first two decades of life. Despite the use of multimodal therapy (chemotherapy, radiation and surgery), the long-term disease-free survival rate of EFT patients is still disappointedly low, particularly in the high-risk groups with metastasis at diagnosis or unfavorable location (1) . Nearly all cases feature a class of chromosomal translocations that fuse the C-terminal DNA-binding domain of an E-twenty-six (ETS) transcription factor to the N-terminal region of the EWS (EWing Sarcoma) gene product (2, 3) . The specificity of these translocations for EFT has now been extensively documented. The most frequent fusion (85% of cases) involves the ETS family FLI1 (Friend Leukemia virus Integration 1) gene as a consequence of the t(11;22)(q24;q12) translocation (4) . EWS/FLI1 behaves as an aberrant transcription factor and is thought to cause transformation through activation or repression of specific target genes (5) . Therefore, the construction of a hierarchy of EWS/FLI1 target genes and the determination of which signaling pathways or networks are affected by this oncogenic protein is essential to design novel therapeutic strategies that could interfere with EFT growth and metastasis.
The Wnt family of secreted glycoproteins includes 19 members in humans that are important regulators of development and homeostasis. They bind to Frizzled receptors and low density lipoprotein receptor-related proteins (LRP)5/6 co-receptors located at the plasma membrane and signal through what have been called canonical and non-canonical pathways (6) . Canonical signaling causes accumulation of b-catenin in the cytosol due to inhibition of its proteasometargeting phosphorylation by glycogen synthase kinase-3b and casein kinase I, which form a complex with the tumour suppressor APC (adenomatous polyposis coli) and Axin proteins. This is followed by translocation to the nucleus, where b-catenin associates with members of the T-cell factor (TCF)/lymphoid enhancer factor (LEF) family of transcription factors and thus regulates gene expression. The TCF/LEF family consists of four members: LEF1, TCF7/ TCF1, TCF7L1/TCF3 and TCF7L2/TCF4. Mutations in Axin, APC and b-catenin have been characterized in numerous human malignancies and the common outcome of these mutations is the accumulation of free b-catenin, which resembles constitutively active Wnt signaling. Non-canonical pathways lead to the activation of the small GTPases, Rho and Rac, and kinases such as Jun N-terminal kinase and protein kinase C or to changes in the levels of Ca 2þ (6) .
Several natural extracellular Wnt antagonists are known, including soluble Frizzled-related receptor proteins, Wnt inhibitory factor (WIF-1) and members of the Dickkopf (DKK-1 to -4) family (7, 8) . DKK-1 simultaneously binds to LRP5/6 and the transmembrane proteins Kremen 1/2 and induces LRP endocytosis, which prevents the formation of Wnt-Frizzled-LRP5/6 receptor complexes and blocks Wnt/b-catenin signaling (9) (10) (11) (12) . Human DKK-1 has wide effects on cell proliferation and differentiation (13) . It induces the proliferation of human adult bone marrow stem cells (14) and inhibits osteoblastic differentiation (15) , which is in line with the finding that high circulating levels of DKK-1 in patients with multiple myeloma are associated with osteolytic lesions (16) . Moreover, glucocorticoids, which are associated with bone loss and osteoporosis, (17) enhance DKK-1 expression in osteoblasts (18) . In contrast, DKK-1 expression promotes preadipocyte differentiation (19) , and in the mouse small intestine and colon, forced Dkk-1 expression inhibits the proliferation of the crypt progenitor cells that is induced by the transcriptional activity of b-catenin/TCF (20, 21) . Recently, it has been shown that exogenous DKK-1 expression promotes neurite formation in EFT cells, possibly by shifting endogenous Wnts from Wnt-Frizzled-LRP complexes to Wnt-Frizzled interactions that transduce non-canonical signals (22) . Thus, DKK-1 seems to have distinct effects depending on the cell type, which agrees with the different effects of Wnt signaling.
We and others have described that transcription of the DKK-1 gene is enhanced by b-catenin/TCF acting on several sites in the promoter region (23) (24) (25) and by 1a,25-dihydroxyvitamin D 3 , the most active metabolite of vitamin D, in colon cancer cells associated to the induction of an epithelial adhesive phenotype (26) . Our group has also reported that DKK-1 is downregulated in human colon cancer (24) , which implies the loss of this negative feedback control of the Wnt/b-catenin pathway in this neoplasia. More recently, we showed that DKK-1 downregulation is partially due to promoter methylation, which is specifically found in 25% of advanced colorectal tumours (27) .
In this study, we report that the human DKK-1 gene is inhibited by the EWS/FLI1 oncogenic transcription factor in EFT cells, as well as in HeLa cells engineered to express an inducible EWS/FLI1 transgene. EWS/FLI1 inhibits b-catenin/TCF-mediated transactivation of the DKK-1 promoter and of a synthetic promoter containing consensusbinding sites for the TCF/LEF family of transcription factors. We also show that EWS/FLI1 binds LEF1, interfering with the formation of b-catenin-LEF1 complexes, and thus with their transcriptional activity. In summary, our results support a general inhibitory effect of EWS/ FLI1 on b-catenin/TCF transcriptional activity that could be most relevant to understand EWS/FLI1-mediated oncogenesis.
Materials and methods
Cell culture EFT cell lines RD-ES and TTC-466 were maintained in RPMI 1640 medium; SK-PN-DW in Iscove's modified Dulbecco's medium; and A673 and human embryonic kidney 293T cells in Dulbecco's modified Eagle's medium. All media were supplemented with 10% fetal calf serum and 2 mM L-glutamine (Invitrogen, Paisley, UK). HeLa pTET-E/F, A673/TR/shEF and A673/TR/ shGFP cells, which have been described elsewhere (28) , were cultured in Dulbecco's modified Eagle's medium supplemented with 10% tetracyclinefree fetal calf serum (Clontech, Mountain View, CA), 2 mM L-glutamine, 100 lg/ml zeozin and 3 lg/ml blasticidin. Induction of the EWS/FLI1 transcript or small hairpin RNA (shRNA) was started by the addition of 1 lg/ml doxycycline (Sigma, St Louis, MO).
Microarrays for analysis of gene expression profiles
Microarray data used in this study have been previously published and are described in detail elsewhere (28, 29) . One data set is comprised of Ewing tumours, neuroblastoma and rhabdomyosarcoma and was used to identify gene expression profiles characteristic of these pediatric tumours (28) . The other data set is comprised of RNA isolated from A673/TR/shEF and A673/TR/ shGFP cells stimulated with doxycycline for 72 h to induce the expression of green fluorescent protein (control), or EWS/FLI1-specific shRNAs, and was used to identify genes regulated by EWS/FLI1 in Ewing tumour cells (29) .
Real-time quantitative reverse transcription-polymerase chain reaction
Real-time quantitative reverse transcription-polymerase chain reaction and primers and Taqman probes sequences specific for EWS/FLI1 and TBP are described elsewhere (28) . The sequences of the primers used to quantify DKK-1 messenger RNA (mRNA) levels were as follows: DKK1-F, 5#-GGCGGGAATAAGTACCAGACC-3#; DKK1-R, 5#-TGCAGGCGAGA-CAGATTTGC-3# and DKK-1 Taqman probe, 5#-FAM-ACAACTAC-CAGCCGTACCCGTGCG-BHQ1-3#. Reactions were run on a RotorGene 6000 (Corbett Research, Sydney, Australia). Cycle threshold (Ct) values for EWS/FLI1, DKK-1 and TBP were calculated using the RotorGene Software and exported to Excel spreadsheets for additional analysis. Relative EWS/FLI1 and DKK-1 expression was calculated as 2 ÀDCt , where DCt 5 Ct EWS/FLI1 or DKK-1 À Ct TBP .
Transfections, plasmids and reporter assays Subconfluent cultures were transfected in triplicate using the jetPEI transfection reagent (PolyPlus Transfection, Illkirch, France) and following the manufacturer's guidelines. The reporter plasmids pTOPFLASH, pFOPFLASH, 4xwtCBF1Luc, 4xmtCBF1Luc and those encoding DKK-1 promoter fragments upstream the Firefly luciferase gene have been described previously (24, 30, 31) . Site-directed mutagenesis of TCF/LEF-binding sites on the À231/þ112 DKK-1 promoter construct was performed using the Stratagene QuikChange II XL Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA), and the wild-type 5#-CTTTG(A/T)(A/T)-3# sites changed into 5#-CTTTGGC-3#. The expression plasmids pMT23-b-catenin, pCDNA3-b-cateninS37Y, pCDNA3-TCF4-VP16 and pCIneo-EWS/FLI1, as well as those expressing control (shGFP) and EWS/FLI1 (shEF) shRNAs, have been described elsewhere (24, 28, 29, 32, 33) . pCIneo-LEF1 encoding an HA-tagged full-length LEF1 complementary DNA was a generous gift from Dr A.García de Herreros (Barcelona, Spain). A Renilla luciferase plasmid (pRL-TK) was used in all experiments as an internal control. Firefly and Renilla luciferase activities were measured separately using the Dual Luciferase reagent kit (Promega, Madison, WI) and a GloMax 96 microplate luminometer (Promega). As a positive control of EWS/FLI1-mediated transactivation, we generated a reporter plasmid containing a fragment of the DAX1 gene promoter obtained from the EFT cell line A4573 and cloned upstream the Firefly luciferase gene in the pGL3basic vector (pGL3-promDAX1/A4573). This fragment comprises a microsatellite sequence present in the DAX1 promoter containing 25 GGAA repeats, which is responsible for EWS/FLI1-mediated transactivation of DAX1, a wellcharacterized EWS/FLI1 direct target gene (29) .
Immunoprecipitation, western blot analysis and antibodies
For coimmunoprecipitation analysis, cells were solubilized in lysing buffer (150 mM NaCl, 50 mM Tris, pH 7.5, 0.2% Nonidet P-40), and extracts were clarified by centrifugation at 12 000g for 30 min at 4°C. Total cell lysates (1.5 mg) were incubated with a high-affinity anti-HA antibody (Roche) for 16 h at 4°C and then incubated, with rotation, with Gammabind G Sepharose (GE Healthcare, Waukesha, WI) for 2 h at 4°C. Beads were collected by centrifugation, washed four times in lysing buffer, dissolved in Laemmli buffer and analyzed by western blot. Following sodium dodecyl sulfatepolyacrylamide gel electrophoresis, proteins were transferred to polyvinylidene difluoride membranes (Millipore Corp., Bedford, MA), and after blocking with 5% low fat milk, filters were incubated with the specific primary antibody. Membranes were then washed in 0.5% Tween 20 in Tris-buffered saline and incubated for 45 min with a horseradish peroxidase-conjugated secondary antibody. After washing in Tris-buffered saline/Tween, membranes were subjected to enhanced chemiluminescence (GE Healthcare) detection analysis. Anti-b-catenin monoclonal antibody was obtained from BD Transduction Laboratories (Lexington, KY), anti-HA monoclonal antibody from Covance (Princeton, NJ), and anti-FLI1 polyclonal antibody from Santa Cruz Biotechnology (Santa Cruz, CA). Anti-mouse and anti-rabbit IgG horseradish peroxidase-conjugated secondary antibodies were purchased from Promega and Jackson ImmunoResearch Laboratories (Suffolk, UK), respectively.
Results

EWS/FLI1 represses DKK-1 expression
We analyzed the gene expression profile regulated by EWS/FLI1 using a previously generated cell model in which EWS/FLI1 protein level could be diminished by a tetracycline-inducible shRNA (A673/ TR/shEF) (28, 29) . Since much attention has now focused on EWS/ FLI1 upregulated genes, we chose to search for specific EWS/FLI1downregulated target genes. Analysis of our transcriptome study and comparison with other studies (34, 35) showed that one of the genes consistently downregulated by EWS/FLI1 in a variety of EWS/FLI1knockdown cell models was DICKKOPF-1 (DKK-1), an extracellular inhibitor of the Wnt-signaling pathway involved in development and disease (36) . Thus, a reduction in the expression of EWS/FLI1 (A673/ TR/shEF cells treated with doxycycline) led to a selective and specific increase in DKK-1 RNA, whereas those of DKK-2 and DKK-4, two other members of the DICKKOPF family, remained unchanged ( Figure 1A , shEF).
We next compared the pattern of DKK family members in the Ewing cell line A673 with another transcriptome analysis designed to compare gene expression patterns between Ewing sarcoma (ES) and two other pediatric small round blue-cell tumours, rhabdomyosarcoma and neuroblastoma (28) . The pattern of expression of DKK family members in control cells (A673/TR/shGFP) perfectly matched that of our tumour samples ( Figure 1A , shGFP). DKK-2 was clearly overexpressed in Ewing sarcoma samples, whereas DKK-4 expression was variable ( Figure 1A) . In contrast, expression of DKK-1 was low in Ewing sarcomas, as well as in the other two neoplasias ( Figure 1A) .
Taken together, these results suggested that the DKK-1 gene was consistently downregulated by EWS/FLI1 in EFT cells and tumours. We used quantitative reverse transcription-polymerase chain reaction to validate these data. Time course experiments showed that treatment with doxycycline caused a slow accumulation of DKK-1 RNA in A673/TR/shEF cells that correlated to the decrease in EWS/FLI1 expression ( Figure 1B ).
Next, we studied whether exogenous EWS/FLI1 protein could regulate the expression of DKK-1 in a different cell context. Treatment of HeLa cells expressing a tetracycline-inducible EWS/FLI1 construct (HeLa TeT-E/F, ref. 28) with doxycycline led to a strong reduction in DKK-1 RNA which correlated to the increase in EWS/FLI1 ( Figure 1C ). Lithium is a well-known glycogen synthase kinase-3b inhibitor EWS/FLI1 inhibits DICKKOPF-1 that activates b-catenin/TCF transcriptional activity, and we have previously reported that it is a positive regulator of DKK-1 expression in HeLa cells (24) . We thus analyzed whether EWS/FLI1 was able to antagonize the effect of lithium on DKK-1 expression. As shown in Figure 1C , EWS/FLI1 reduced the effect of lithium on DKK-1 expression ( Figure 1C ). Likewise, DKK-1 expression was reduced in HEK-293T cells transiently transfected with an EWS/FLI1-expressing construct, both in the absence and presence of lithium (data not shown). Thus, our results indicated that EWS/FLI1 repressed both basal and b-catenin/TCF-mediated DKK-1 expression and that this property seems to be intrinsic to the EWS/FLI1 protein and independent of the cell context. EWS/FLI1 inhibits b-catenin/TCF-mediated transcription of DKK-1 We next examined whether EWS/FLI1 altered DKK-1 transcription using a 2.2 kb fragment of the human DKK-1 promoter cloned upstream a luciferase reporter gene (24) . Consistent with DKK-1 expression studies, EWS/FLI1 expression in HEK-293T cells inhibited basal DKK-1 promoter activity (56%; Figure 2A ). Analysis of the DNA sequence of this promoter fragment failed to identify putative ETSbinding sites that could be recognized by the EWS/FLI1 protein, and thus, we hypothesized that repression of DKK-1 expression by EWS/ FLI1 should be achieved by an indirect mechanism. Previous studies from our group and others have demonstrated that the DKK-1 promoter presents multiple TCF/LEF-binding sites (23-25) ( Figure 2B ). Thus, we analyzed whether EWS/FLI1 was able to interfere with b-catenin/TCF-dependent transcription of DKK-1. As shown in Figure 2A , EWS/FLI1 abolished activation of the DKK-1 promoter by either wild-type (70%) or a constitutively active form of b-catenin (83%) that cannot be degraded (b-catenin S37Y, b-cat S37Y ) (Figure 2A ). To confirm that the effect of EWS/FLI1 was mediated through the TCF/LEF-binding sites, we used a series of deletion constructs and mutants of the DKK-1 promoter ( Figure 2B ). Our results showed that b-catenin-mediated induction of the DKK-1 promoter strongly correlated with the number of TCF/LEF-binding sites, and EWS/ FLI1 efficiently inhibited all constructs harboring TCF/LEF sites ( Figure 2C ). Moreover, we generated a point mutant for the shorter promoter construct (À231/þ112 ÃÃ ) that destroys its two TCF/LEF sites ( Figure 2B ). Figure 2D shows that b-catenin promotes a 3.5-fold increase over the basal transcription level of the wild-type À231/þ 112 construct, which is efficiently reduced by EWS/FLI1. In the mutant construct, b-catenin-mediated induction is blocked and EWS/FLI1 has no additional effects, indicating that EWS/FLI1 interferes with b-catenin activation of TCF/LEF sites.
EWS/FLI1 inhibits b-catenin/TCF transcriptional activity
The antagonism between EWS/FLI1 and b-catenin/TCF signaling on the DKK-1 promoter raised the question of whether this effect was specific for DKK-1 or in contrast a general action of EWS/FLI1 on b-catenin/TCF transcription. To assess this issue, we used the pTOP-FLASH and pFOPFLASH plasmids that respectively contain three copies of the optimal TCF/LEF motif CTTTGAT or three copies of the mutant motif CTTTGGC upstream of a minimal c-FOS promoter and the Firefly luciferase gene, which have been extensively used to study b-catenin/TCF transcriptional activity (30) . Transient expression of EWS/FLI1 in HEK-293T cells efficiently blocked activation of the pTOPFLASH reporter by b-cat S37Y (Figure 3 , left panel). This effect was specific since activation of the Notch pathway reporter 4xwtCBF1Luc by Notch intracellular domain was unaffected by EWS/FLI1 (Figure 3 , right panel). According to these results, it should be expected that b-catenin/TCF response would be impaired in EFT cells expressing endogenous EWS/ETS fusions. To analyze the activity of the canonical Wnt/b-catenin pathway in EFT cells, we evaluated the pTOPFLASH and pFOPFLASH transcriptional response of several Ewing cell lines to b-cat S37Y . Our data show that basal Wnt/b-catenin signaling is low (ratio between pTOPFLASH and pFOPFLASH activity ,2-fold) in non-stimulated EFT cells ( Figure 4A , compare white columns). In addition, we found that b-cat S37Y was unable to activate b-catenin/TCF-dependent transcription in EFT cells as it does in HEK-293T cells, which were used as a positive control ( Figure 4A ). Therefore, if b-catenin/TCF-dependent transactivation is impaired by EWS/FLI1 in EFT cells, EWS/FLI1 knockdown should restore the responsiveness to a positive stimulus of the b-catenin/TCF pathway. Precisely, expression of b-cat S37Y led to a significant increase in b-catenin/TCF transcriptional activity in the EFT cell lines A673/TR/shEF and RD-ES upon EWS/FLI1 silencing following doxycycline treatment ( Figure 4B ) or transient transfection of a shRNA targeting EWS/FLI1 ( Figure 4C ), respectively. A reporter plasmid containing a fragment of the DAX1 gene promoter, a well-characterized EWS/FLI1 direct target gene (29, 35 ) (see Materials and Methods), confirmed that transient expression of an EWS/FLI1 shRNA in RD-ES cells efficiently inhibits (58%) Figure 4D ), demonstrating that it reduces EWS/FLI1 protein level. These data support that EWS/FLI1 inhibits the transcriptional activity of b-catenin-TCF complexes in EFT cells.
Our results hint that at least a set of b-catenin/TCF target genes should be inhibited by EWS/FLI1. To approach this issue, we performed a bioinformatics analysis, the Gene Set Enrichment Analysis (37) . Briefly, Gene Set Enrichment Analysis determines whether one list of genes (in our case, genes that share a determined transcription factor-binding site in their promoter) is enriched near the top of a second rank-ordered gene list (in our case, the list of genes regulated by EWS/FLI1). We tested 615 gene sets that contain genes that share a transcription factor-binding site defined in the TRANSFAC database (version 7.4, http://www.gene-regulation.com/), conserved across the human, mouse, rat and dog genomes (38) against our ranked data set according to Student's t-test P-values. Gene Set Enrichment Analysis identified several data sets that are significantly enriched among the EWS/FLI1-downregulated genes (supplementary Table S1 is available at Carcinogenesis Online). Interestingly, one of them was the data set corresponding to genes that share a binding site for LEF1 (CTTTGT), indicating that repression of TCF/LEF target genes is a general characteristic of the EWS/FLI1 protein. Additionally, we compared the list of genes downregulated by EWS/FLI1 with the list of TCF/LEF target genes available in 'The Wnt homepage' (http: //www.stanford.edu/$musse/pathways/targets.html). We noted that a significant proportion of the genes upregulated by TCF/LEF were repressed by EWS/FLI1 in the EFT cell line A673 (supplementary Table S2 is available at Carcinogenesis Online). Moreover, we also observed that other components of the Wnt pathway, not previously identified as b-catenin/TCF target genes, were also downregulated by EWS/FLI1, such as KREMEN1 (a receptor for DKK-1), CTNNBIP1 (b-catenin interacting protein) and DACT1 (Dapper, antagonist of b-catenin, homolog 1). Taken together, these findings indicate that repression of TCF/LEF target genes is a general characteristic of the EWS/FLI1 protein.
Constitutively active TCF4 restores DKK-1 transcription in EFT cells
Since our results showed that EFT cells had an impaired response to b-catenin-TCF complexes, we investigated the effect of b-catenin on DKK-1 transcription in A673 cells. As expected, b-catenin was unable to stimulate transcription from the DKK-1 promoter, whereas it induced a 4.5-fold increase in HEK-293T cells ( Figure 5A ). Interestingly, a constitutively active form of TCF4 (TCF4-VP16) activated transcription in A673 and other EFT cell lines as it does in HEK-293T cells ( Figure 5A ; data not shown). Likewise, the pTOPFLASH reporter, which was unresponsive to b-catenin in A673 cells, was activated .10-fold by TCF4-VP16 ( Figure 5B ). These data indicated that EWS/FLI1 cannot prevent TCF binding to Wnt-responsive promoters although it efficiently inhibits transcriptional activation by b-catenin.
EWS/FLI1 interferes with b-catenin-LEF1 complex formation
Transcription of Wnt target genes is dependent on b-catenin-TCF interaction. Experiments were thus performed to investigate whether EWS/FLI1 interferes with the ability of b-catenin to interact with LEF1, a TCF/LEF family member. HEK-293T cells were cotransfected with b-cat S37Y , LEF1-HA and either EWS/FLI1 or an empty vector. Data showed that the amount of b-catenin coimmunoprecipitated with LEF1-HA was clearly reduced in the presence of EWS/FLI1 ( Figure 6A ), which indicates that this aberrant transcription factor inhibits b-catenin-LEF1 complex formation. Moreover, EWS/FLI1 was specifically immunoprecipitated into the complex ( Figure 6A ). Interestingly, in a parallel immunoprecipitation with b-catenin antibodies, EWS/FLI1 was only barely detected after a long exposure (data not shown), suggesting that EWS/FLI1 might bind LEF1 preferentially or even compete with b-catenin for LEF1 binding.
We observed a slight decrease in the total amount of b-catenin protein upon expression of EWS/FLI1 that was variable between experiments. To discard that such possible effect on b-catenin level was responsible for the EWS/FLI1 effect observed on b-catenin-LEF1 complex formation, we performed a new experiment in which cells were transfected with different concentrations of the EWS/FLI1 expression plasmid. On this experiment ( Figure 6B ), the level of bcatenin stayed fairly constant at three different EWS/FLI1 doses ( Figure 6B , bottom panels), whereas there was a clear decrease in the amount of b-catenin that binds LEF1 with increasing EWS/FLI1 concentrations ( Figure 6B, upper panel) , supporting that EWS/FLI1 certainly inhibits b-catenin-LEF1 complex formation independently of a possible and slight effect on b-catenin level.
Discussion
EWS/ETS fusion proteins are associated with tumourigenesis in the Ewing family of tumours mainly because they act as abnormal transcription factors. Thus, identification of the genes regulated by these oncogenic proteins represents a key aspect in the understanding of the molecular pathology of these highly malignant tumours. Here, we demonstrate that the Wnt inhibitor DKK-1 is a transcriptional target of EWS/FLI1. Expression of DKK-1 is inhibited by EWS/FLI1 and its repression in EFT cells released in the presence of EWS/FLI1 shRNA. This is in agreement with results from microarray analyses (34, 35) , suggesting that DKK-1 is an EWS/FLI1 target gene. Although in some cases negative response elements have been described in the promoter region of prospective genes, most frequently, interference between a transcription factor and other transcription factors or pathways is responsible for the repression. In such cases, the transcription factor can compete with the binding of other transcription factors to their DNA-binding sites or alter their binding dynamics and/or transactivation activity via protein-protein interaction (39, 40) . In this regard, we have shown that EWS/FLI1 can antagonize b-catenin/TCF-mediated transcription of the DKK-1 gene, suggesting that interference with b-catenin-TCF complexes may be one of the mechanisms responsible for negative transcriptional regulation by EWS/FLI1.
Basal transcription from the DKK-1 promoter is also inhibited by EWS/FLI1. Since it has been reported that EFT cells express endogenous Wnt proteins (41) , a plausible explanation is that EWS/FLI1 antagonizes the effect of these factors on DKK-1 transcription. However, we cannot rule out other possibilities. Direct binding of EWS/ FLI1 to the DKK-1 promoter sequences seems unlikely, since 
EWS/FLI1 inhibits DICKKOPF-1
Miyagawa et al. (42) have recently reported binding of EWS/FLI1 to the DKK-2 promoter but failed to detect binding to the DKK-1 promoter using chromatin immunoprecipitation assays. In contrast with our data and the gene expression profile studies mentioned above (34, 35) , these authors reported no effect of EWS/FLI1 on DKK-1 transcription.
The most important conclusion of our study is that the canonical Wnt/b-catenin pathway is constitutively repressed by EWS/FLI1 in EFT cells, suggesting that inhibition of this pathway is an essential step in EWS/FLI1-mediated oncogenesis. This is an unexpected finding since constitutive aberrant activation of Wnt/b-catenin signaling is a frequent event in carcinomas (36) . However, it was also recently shown by Matushansky et al. (43) that inactivation of the Wnt canonical pathway is also a necessary step to the development of high-grade undifferentiated pleomorphic sarcoma. These authors showed that the Wnt/b-catenin antagonist DKK-1 is highly expressed in this tumour and that overexpression of DKK-1 in mesenchymal stem cells induces this type of sarcoma. Although inactivation of the Wnt/b-catenin pathway seems to be mediated by different mechanisms in both EFTs and undifferentiated pleomorphic sarcoma (DKK-1 is strongly repressed by EWS/FLI1 in EFTs), these results indicate that keeping turned off the Wnt/b-catenin pathway is necessary for at least some types of sarcoma. Thus, in contrast to carcinomas, inhibition of Wnt signaling seems to be pro-oncogenic in mesenchymal stem cells.
Since DKK-2 is expressed at high level in EFT cell lines and tumours, it could potentially contribute to the inhibition of the Wnt/ b-catenin pathway. Nonetheless, the role of DKK-2 on Wnt signaling is dual, behaving as an inhibitor or an activator depending on cellular context (8) . In the case of EFT cells, it seems that DKK-2 is unable to suppress Wnt signaling since treatment of Ewing cells with Wnt3aconditioned medium leads to accumulation of cytosolic and nuclear b-catenin (supplementary Figure S1 is available at Carcinogenesis Online, also see refs 22, 41) , a sign that the upstream Wnt pathway is active.
Although b-catenin accumulates in the cytosol of EFT cells in response to Wnt proteins (supplementary Figure S1 is available at Carcinogenesis Online, refs 22,41) and enters the nucleus (supplementary Figure S1 is available at Carcinogenesis Online), b-catenin/ TCF-mediated transcription is blocked. Our data using TCF4-VP16 indicate that EWS/FLI1 cannot prevent TCF binding to Wnt-responsive promoters and so suggest that EWS/FLI1 must interfere upstream. This is in agreement with coimmunoprecipitation experiments that show that EWS/FLI1 binds LEF1 and interferes with b-catenin binding, which could explain the inhibition of b-catenin/TCF transcriptional activity. Unfortunately, we have not been able to detect endogenous binding between EWS/FLI1 and LEF1 in EFT cells, probably due to the unsuitability of the available antibodies. Future work will be necessary to further understand the molecular mechanism behind this inhibition. Interestingly, EWS/FLI1 specifically targets the Wnt canonical pathway since Wnt signaling through a non-canonical Jun N-terminal kinase-dependent mechanism is active in EFT cells and leads to neurite outgrowth (22) .
According to our data, EWS/FLI1 exerts a general effect on b-catenin/TCF-mediated transcription in Ewing tumour cells by interfering with the formation of b-catenin-TCF complexes. In this way, multiple b-catenin/TCF gene targets are affected, making it difficult for the identification of specific genes that could be involved in Ewing tumourigenesis. One of these genes could be DKK-1 itself (see below). However, we think that since b-catenin/ TCF-dependent transcription is globally impaired in Ewing tumours, the functional importance of this pathway on Ewing tumourigenesis should be also addressed from a global approach. In this regard, the results presented in this study provide some important findings that could be useful to ascertain the functional importance of blocking Wnt/b-catenin signaling in Ewing tumours. Additionally, mapping the regions that are involved in the interaction between EWS/FLI1 and LEF1 (and possibly other members of the TCF/LEF family of transcription factors) should be helpful to design molecules with the ability to block this binding.
DKK-1 inhibition seems to be relevant for EWS/FLI1-mediated tumourigenesis as ectopic expression of DKK-1, but not DKK-2, in the EFT cell line SK-ES1 resulted in the suppression of tumour growth in immunodeficient mice (42) . This is in agreement with our data in DLD-1 colon cancer cells in which expression of DKK-1 decreased cell growth in vitro and tumour formation in immunodeficient mice. DLD-1 cells bear a truncated APC gene and so have a constitutively active Wnt/b-catenin pathway, so it seems that DKK-1 has antitumoural effects independently of the antagonism of b-catenin/ TCF transcriptional activity. These b-catenin-independent effects have also been described in H28 and MS-1 mesothelioma, HeLa cervical, and JAR and JEG3 human placental choriocarcinoma cancer cells (44) (45) (46) . Activation of the Jun N-terminal kinase pathway might be involved in some of these tumour suppressor effects (44, 46) . Therefore, inhibition of DKK-1 by EWS/FLI1 may be of relevance for the progression of Ewing sarcoma, and further studies will be necessary to unveil the mechanisms responsible for the tumour suppressor activity of DKK-1 in EFT cells and to determine whether DKK-1 administration could be a prospective therapeutic strategy against this neoplasia.
